SCHEMBL6821994

SCHEMBL6821994

CC(C)n1nc(-c2c(-c3ccccc3)nn3cc(C(=O)N4C[C@@H](C)O[C@@H](C)C4)ccc23)ccc1=O

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
ADORA1 P30542 1/20 0.38
HSD17B10 Q99714 2/20 0.38
TSHR P16473 2/20 0.38
NPC1 O15118 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KDM4E B2RXH2 1/20 0.38
TP53 P04637 1/20 0.35
NAMPT P43490 1/20 0.35
MAPK8 P45983 1/20 0.35
MAPK9 P45984 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6818699 0.87 HSD17B10 (0.41) HPGDALDH1A1LMNAMEN1KMT2A
SCHEMBL6818692 0.87 HSD17B10 (0.41) HPGDALDH1A1LMNAMEN1KMT2A
SCHEMBL6821936 0.85 POLB (0.44) HPGDALDH1A1ADORA1TSHRTP53
SCHEMBL6818525 0.85 ALDH1A1 (0.38) HPGDALDH1A1LMNAMEN1KMT2A
SCHEMBL6821976 0.84 TDP1 (0.41) HPGDALDH1A1LMNAMEN1KMT2A
SCHEMBL6822022 0.84 ADORA1 (0.45) HPGDKMT2ASMN1; SMN2ADORA1TP53
SCHEMBL6821514 0.80 MEN1 (0.44) HPGDALDH1A1LMNAMEN1KMT2A
SCHEMBL6824345 0.80 ADORA1 (0.42) MEN1KMT2AADORA1TP53MAPK8
SCHEMBL6821461 0.79 HRH3 (0.41) ALDH1A1LMNAMEN1KMT2AADORA1
SCHEMBL6824772 0.78 ADORA1 (0.44) KMT2ASMN1; SMN2ADORA1KDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 HPGD 684/4885ALDH1A1 564/4885LMNA 4472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.